Back to Blog
With other variants, vaccines have been found to provide higher levels of protection against severe outcomes compared to mild disease.(2-4) Understanding the effectiveness against more severe end points such as hospital admissions is crucial in evaluating the risk Delta poses on the population and the consequences of easing non-pharmaceutical interventions. However, the very recent emergence of the variant and the relatively low case numbers meant that it was not possible to estimate VE against severe disease. This provided important evidence that despite modest reductions in protection, vaccines remain effective against Delta. Guys and St Thomas’s Hospital NHS Trust, London, UK We recently reported vaccine effectiveness ((VE) estimates against symptomatic disease with the Delta (B.1.617.2) variant.(1) After a full course, VE reached 88% with the Pfizer/BioNTech BNT162b2 vaccine and 67% with the AstraZeneca ChAdOx1 AZD1222 vaccine. Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, UK 5. NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, United Kingdom 4. NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom 3. Public Health England, London, United Kingdom 2. Julia Stowe1, Nick Andrews1,2, Charlotte Gower1, Eileen Gallagher1, Lara Utsi1, Ruth Simmons1, Simon Thelwall1, Elise Tessier1, Natalie Groves1, Gavin Dabrera1, Richard Myers1, Colin Campbell1,2, Gayatri Amirthalingam1,2, Matt Edmunds1, Maria Zambon1,3, Kevin Brown1,2, Susan Hopkins1,4, Meera Chand1,5, Mary Ramsay1,2, Jamie Lopez Bernal1,2,3 1. East African Consortium for Clinical ResearchĮffectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant.Worldwide Antimalarial Resistance Network (WWARN).TREAD (The Research Ethics Application Database). Sub-Saharan Congenital Anomalies Network.Member Sites Our network of members around the world.
0 Comments
Read More
Leave a Reply. |